NEWS AND VIEWS

reach52 partners with Biocon to bring affordable quality insulin to the Philippines

reach52 has partnered with Biocon Biologics to bring affordable quality insulin to the Philippines, supporting Biocon’s commitment to make recombinant human insulin available for less than 10 US cents in low- and middle-income countries.  

Working with the local governments of the municipalities of Pototan and Cuartero in the provinces of Iloilo and Capizthe goal is to strengthen timely access to medicines, screening and care in diabetes.  

This is a part of Biocon Biologics’ commitment to unlock universal access to quality insulins through its “Mission 10 cents” program by making recombinant human insulin (rh-insulin) available for less than 10 US cents (around P5) per day in low- and middle-income countries. 

“As a committed global insulins player, Biocon Biologics seeks to shift the access paradigm for patients in need of quality insulins across the globe through its ‘Mission 10 cents’ program. We are pleased to partner with the Philippines government for a long-term, integrated diabetes management program enabling affordable access for patients,” said Dr. Christiane Hamacher, Biocon Biologics CEO. 

“We are aware of the challenges associated with the affordability of insulin therapy even after 100 years of its discovery and are collaborating with like-minded partners to ensure pricing does not impede access for patients who need this life-saving therapy,” Hamacher added. 

Biocon Biologics India Ltd., a fully integrated ‘pure play’ biosimilars company, is bringing its integrated diabetes management program to the Philippines to enable affordable access to quality insulins. 

Biocon entered into a memorandum of understanding with the local governments of the municipalities of Pototan and Cuartero in the provinces of Iloilo and Capiz, respectively, as well as with the social enterprise reach52, with the aim of developing a scalable framework to strengthen access to timely, affordable and quality diabetes care at the municipal level in the Philippines. 

This is a part of Biocon Biologics’ commitment to unlock universal access to quality insulins through its “Mission 10 cents” program by making recombinant human insulin (rh-insulin) available for less than 10 US cents (around P5) per day in low- and middle-income countries. 

“As a committed global insulins player, Biocon Biologics seeks to shift the access paradigm for patients in need of quality insulins across the globe through its ‘Mission 10 cents’ program. We are pleased to partner with the Philippines government for a long-term, integrated diabetes management program enabling affordable access for patients,” said Dr. Christiane Hamacher, Biocon Biologics CEO. 

The Philippines is among the top five countries in Western Pacific Region with high diabetes prevalence. Data from the Department of Health puts the number of Filipinos suffering from diabetes at over 4 million. 

“Mission 10 cents is not only about offering Biocon’s rh-insulin at a lower price but it is a partnership with diverse stakeholders that goes beyond the product to transform the patient ecosystem and contribute to achieving better health outcomes and reduce cost of care for millions of people living with diabetes in the Philippines,” said Dr. Alexander Zach, Global Head of Market Access & Policy of Biocon Biologics 

“With diabetes being one of the most worrying and growing global diseases, our role at reach52 is to find partnerships to help create health for all by finding innovative health solutionsI am confident that Biocon Biologics will deliver on that promise and bring affordable insulin and resources to help strengthen local health systems,” added Edward Booty, reach52 CEO. 

Read the coverage here 

https://bit.ly/30BBYBI 

https://www.sunstar.com.ph/article/1872405/ILOILO/Business/Biocon-Biologics-to-roll-out-Mission-10-cents-in-PH 

https://www.pressreader.com/philippines/businessmirror/20201005/281865825927226?fbclid=IwAR136CYsGRGIu5SOIj85Rk_t3DBiCDgWV8WTdVXsm6iquH7nJp-xqxIzhsU 

en_GBEnglish (UK)